Paliperidone Palmitate 3-Month Formulation
Mania
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Mania cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | BBB |
LITHIUM, ELEMENTAL University of Cincinnati | Phase 4 | BBB |
Seroquel® University of Cincinnati | Phase 4 | BBB |
Opc-34712 Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | BB |
Valproic Acid Weill Medical College of Cornell University | Phase 4 | BB |
View all 28 →
Same molecule, other indications
Paliperidone Palmitate 3-Month Formulation is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →